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Alopecia areata (AA) is a common dermatological disease, which affects nearly 2% of the general population.
Association of AA with atopic disease has been repeatedly reported. Loss-of-function mutations in the filaggrin
gene (FLG) may be considered as promising candidates in AA, as they have been observed to be a strong risk
factor in atopic dermatitis. The FLG mutations R501X and 2282del4 were genotyped in a large sample of AA
patients (n¼ 449) and controls (n¼ 473). Although no significant association was observed in the patient sample
overall, FLG mutations were significantly associated with the presence of atopic dermatitis among AA patients.
Furthermore, the presence of FLG mutations had a strong impact on the clinical course of AA in comorbid
patients. For example, 19 of the 22 mutation carriers among AA patients with atopic dermatitis showed a severe
form of the disease (P¼ 0.003; odds ratio (OR)¼ 5.47 (95% confidence interval (CI): 1.59–18.76)). In conclusion,
our data suggest that when AA occurs in conjunction with FLG-associated atopic disorder, the clinical
presentation of AA may be more severe.
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INTRODUCTION
Alopecia areata (AA) is a common skin disease presenting
with patchy hair loss, which affects approximately 1–2% of
the general population (Safavi et al., 1995). Its etiopathogene-
sis is incompletely understood, but it is thought to be a tissue-
specific autoimmune disease directed against the hair follicle.
Family and twin studies suggest strongly that genetic
factors, which probably act in a polygenic fashion, play an
important role in the development of AA (Jackow et al., 1998;
Blaumeiser et al., 2006). Various genes related to immune
response have been postulated to be associated with AA
(Galbraith and Pandey, 1995; Tazi-Ahnini et al., 2000,
2002a, b; Barahamani et al., 2002), but only the involvement
of the major histocompatibility complex has been confirmed
through independent replication (Duvic et al., 1995; Colombe
et al., 1999; de Andrade et al., 1999; Entz et al., 2006).
An association of AA with atopic disease has been
reported in several studies (Ikeda, 1965; Young et al., 1978;
Tan et al., 2002; Goh et al., 2006). Mutations in the filaggrin
gene (FLG) have been observed to be a strong risk factor for
atopic dermatitis (Palmer et al., 2006; Ruether et al., 2006;
Weidinger et al., 2006; Stemmler et al., 2007; Barker et al.,
2007; Morar et al., 2007; Weidinger et al., 2007), and we
therefore hypothesized that FLG mutations may also play a
role in AA, particularly in those patients with comorbid
atopic disease. As comorbidity with atopic disease has been
associated previously with a severe form of AA (Ikeda, 1965;
Goh et al., 2006), we also wished to test whether this effect,
if present in our sample, is influenced by the presence of
FLG mutations.
RESULTS
The two previously reported loss-of-function mutations of the
FLG gene, R501X and 2282del4, were genotyped in our cases
and controls. The genotype distributions of the two mutations
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observed in patients and controls are shown in Table 1.
Distributions of genotypes were consistent with Hardy–Wein-
berg equilibrium for 2282del4 in both groups and for R501X
in controls. The distribution of genotypes for R501X
significantly departed from Hardy–Weinberg proportions in
patients (P¼ 6.4107).
In control chromosomes, mutation frequencies were 1.5%
for R501X and 2.4% for 2282del4. This is similar to
frequencies reported in other European populations (Palmer
et al., 2006). Two patients were homozygous for R501X and
two patients were compound heterozygotes for R501X and
2282del4. No significant differences in genotype or allele
frequencies between patients and controls were observed for
either of the two mutations (Table 1). It is interesting to note,
however, that all homozygotes and compound heterozygotes
were observed among patients. Given the rarity of these
genotypes, no real conclusions can be drawn concerning a
possible effect of these genotypes on the risk to develop AA.
As the two mutations are considered to be functionally
equivalent, and since the observed effects of the two
mutations in our sample were similar, we combined the
two mutations for the purposes of the detailed analyses
(Table 2). Only patients for whom both mutations had been
characterized were included in the analyses.
Thirty-four percent of our patients had a history of atopic
dermatitis (145/430). Among them were 37 patients with a
history of atopic dermatitis and asthma, and 27 with a history
of atopic dermatitis, asthma and allergic rhinitis. We found
highly significant differences in the frequency of FLG
mutations in patients with atopic dermatitis (P¼0.005),
Table 1. Frequency of FLG mutations R501X and 2282del4 in alopecia areata patients and controls
Genotype distribution (%) P-value1 Allele frequency P-value2
AA Aa aa A A
R501X Controls (n=469) 455 (97.0) 14 (3.0) 0 0.985 0.015
Patients (n=444) 430 (96.8) 12 (2.7) 2 (0.5) 0.730 0.982 0.018 0.713
2282del4 Controls (n=458) 436 (95.2) 22 (4.8) 0 0.976 0.024
Patients (n=435) 403 (92.6) 32 (7.4) 0 0.123 0.963 0.037 0.129
1P-value from the Cochran–Armitage trend test. P-values were not corrected for multiple testing.
2P-value from the Fischer’s exact test. P-values were not corrected for multiple testing.
Table 2. Frequency of combined FLG null mutations in alopecia areata patients, their subgroups, and controls
Genotype distribution (%) Allele frequency
AA Aa aa P-value1 A a P-value2 Odds ratio (95% CI)
Controls (n=449) 413 (92.0) 36 (8.0) 0 0.960 0.040
Patients (n=430) 386 (89.8) 40 (9.3) 4 (0.9) 0.156 0.944 0.056 0.146 1.42 (0.91–2.20)
Atopic dermatitis (n=145) 123 (84.8) 20 (13.8) 2 (1.4) 0.006 0.917 0.083 0.005 2.16 (1.27–3.69)
Atopic dermatitis+asthma (n=37) 26 (70.3) 10 (27.0) 1 (2.70) 0.001 0.838 0.162 0.0001 4.63 (2.30–9.35)
Atopic dermatitis+asthma+allergic rhinitis (n=27) 19 (70.4) 7 (25.9) 1 (3.7) 0.001 0.833 0.167 0.001 4.79 (2.17–10.55)
Mild AA3 (n=192) 178 (92.7) 14 (7.3) 0 0.873 0.964 0.037 0.875 0.91 (0.48–1.70)
Severe AA4 (n=238) 208 (87.4) 26 (10.9) 4 (1.7) 0.017 0.929 0.071 0.014 1.84 (1.14–2.98)
FH+5 (n=120) 109 (90.8) 10 (8.3) 1 (0.8) 0.588 0.950 0.050 0.587 1.26 (0.65–2.46)
FH6 (n=306) 274 (89.5) 29 (9.5) 3 (1.0) 0.145 0.943 0.057 0.138 1.45 (0.90–2.34)
Onset age p20 (n=194) 177 (91.2) 16 (8.3) 1 (0.5) 0.649 0.954 0.046 0.650 1.16 (0.65–2.08)
Onset age 420 (n=236) 209 (88.6) 24 (10.2) 3 (1.3) 0.688 0.936 0.064 0.063 1.63 (0.99–2.67)
1P-value from the Cochran–Armitage trend test. P-values were not corrected for multiple testing.
2P-value from the Fischer’s exact test. P-values were not corrected for multiple testing.
3Patients with patchy alopecia areata (one or more circumscribed patches of hair loss).
4Patients with alopecia totalis (100% loss of scalp hair without loss of body hair), alopecia totalis/universalis (100% scalp hair loss with variable loss of body
hair), and alopecia universalis (100% of both scalp and body hair).
5Defined as history of at least one first- or second-degree relative with alopecia areata.
6Defined as no history of first- or second-degree relative with alopecia areata.
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atopic dermatitisþ asthma (P¼ 0.0001), and atopic dermatitisþ
asthmaþ allergic rhinitis (P¼ 0.001). The associated odds
ratios (ORs) are given in Table 2. Subdividing patients
according to family history of AA (FHþ , FH) and age at
onset revealed no significant associations in the respective
subgroups (Table 2).
In a subsequent step, we tested the effect of comorbidity
and FLG mutations on the severity of AA (Table 3, see
Materials & Methods for detailed description of phenotype
classification). While the frequency of atopic dermatitis was
similar among mildly and severely affected individuals
(P¼0.474), the combination of atopic dermatitisþ asthma
(P¼0.009) and atopic dermatitisþ asthmaþ allergic rhinitis
(P¼0.001) was significantly associated with a severe course
of disease. To test whether the presence of FLG mutations
identifies a subgroup of atopic disease more likely to have
severe AA, we analyzed mutation carriers and non-carriers
separately. The presence of FLG mutations among comorbid
patients was strongly associated with a severe course of the
disease (Table 3). The odds ratio among mutation carriers
raised from 5.47 (1.59–18.76, P¼0.003) in AA patients with
atopic dermatitis to 8.38 (1.06–66.03, P¼ 0.027) in patients
with atopic dermatitisþ asthma and 14.20 (0.81–247.6,
P¼0.01) in patients with atopic dermatitisþ asthmaþ
allergic rhinitis. In non-carriers, only a small effect was seen
in the subgroup of patients with atopic dermatitisþ
asthmaþ allergic rhinitis (OR¼3.16 (95% CI: 1.03–9.69),
P¼0.036).
DISCUSSION
The results of our study clearly demonstrate that FLG
mutations are observed at an increased frequency among
AA patients with a history of atopic dermatitis. This finding
had been anticipated since previous work has suggested that
atopic dermatitis is the core phenotype associated with FLG
mutations (Palmer et al., 2006). Thirty-four percent of the AA
patients in our sample were comorbid for atopic dermatitis.
This high rate of comorbidity supports previous observations
of an association between AA and atopic disorders (Ikeda,
1965; Young et al., 1978; Tan et al., 2002; Goh et al., 2006).
However, the comorbidity rate observed in our sample may
not be an accurate reflection of the true comorbidity between
the two disorders. First, history of an atopic disorder was
assessed in our sample by taking clinical history, without
confirmation through laboratory tests or review of medical
records. We believe, however, that (1) the rate of diagnostic
misspecification was small, as the clinical interviews were
performed by an experienced medical doctor who asked
additional questions if information from patients was unclear
and (2) the frequency of FLG mutations in our AA patients
with atopic dermatitis (combined carrier frequency of 15.2%)
was similar to the frequency observed in a large sample
of well-characterized atopic dermatitis patients of mainly
German origin (combined carrier frequency of 16.7%)
(Marenholz et al., 2006). Second, the majority of our patients
were recruited from a clinical setting, which may have
resulted in a higher rate of comorbidity than is the case in
population-based samples.
Comorbidity with atopic disease has been associated
previously with a severe form of AA (Ikeda, 1965; Goh et al.,
2006), and we can confirm this for the groups of patients with
atopic dermatitisþ asthma and atopic dermatitisþ
asthmaþ allergic rhinitis. Our molecular data suggest that
this effect is driven almost exclusively by the presence of FLG
mutations. In the absence of FLG mutations, comorbidity
with atopic disorder has no or very little effect on the severity
of AA. Filaggrin plays an important role as a protein in the
formation of the epidermal barrier, through binding to and
aggregating with the keratin cytoskeleton (Irvine and McLean,
2006). Our findings therefore suggest that an epidermal
barrier defect contributes to a severe course of AA.
MATERIALS AND METHODS
Subjects
Four hundred and forty-nine AA patients (298 women and 151 men)
aged 5–82 years (mean age: 52.5) were recruited from the outpatient
hair clinics of four Departments of Dermatology, that is the
University Hospitals at Antwerp and Gent (n¼ 260), Du¨sseldorf
Table 3. Association of filaggrin mutations with severity of AA in comorbid patients
Patchy AA (n =192) AT/AU (n =238)
n % n % P-value1 Odds ratio (95% CI)
Atopic dermatitis 61 31.8 84 35.3 0.474 1.17 (0.78–1.75)
Filaggrin null 3 1.6 19 8.0 0.003 5.47 (1.59–18.76)
Filaggrin wt 58 30.2 65 27.3 0.521 0.87 (0.57–1.32)
Atopic dermatitis+asthma 9 4.7 28 11.8 0.009 2.71 (1.25–5.89)
Filaggrin null 1 0.5 10 4.2 0.027 8.38 (1.06–66.03)
Filaggrin wt 8 4.2 18 7.6 0.159 1.88 (0.80–4.43)
Atopic dermatitis +asthma+allergic rhinitis 4 2.1 23 9.7 0.001 5.03 (1.71–14.80)
Filaggrin null 0 0.0 8 3.4 0.01 14.202 (0.18–247.6)
Filaggrin wt 4 2.1 15 6.3 0.036 3.16 (1.03–9.69)
AA, alopecia areata; AT/AU, alopecia totalis and/or universalis, CI, confidence interval.
1P-value from the Fischer’s exact test. P-values were not corrected for multiple testing.
2Because one of the cells contains a zero, the OR has been computed adding 0.5 to each cell.
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(n¼ 107), and Bonn (n¼ 17) and from a private dermatology
practice in Wesseling (n¼ 65). Clinical data were obtained from
all patients, including age at onset and family history. AA type was
determined according to the AA investigational assessment guide-
lines (Olsen et al., 2004) and patients were categorized as having
either patchy alopecia, alopecia totalis (AT), alopecia totalis/
universalis (AT/AU), or alopecia universalis (AU). Patchy
alopecia is defined as one or more circumscribed patches of hair
loss, AT is defined as 100% loss of scalp hair without loss of body
hair, AT/AU is defined as 100% scalp hair loss with variable
loss of body hair, and AU is defined as 100% loss of both scalp
and body hair. Assessment of severity was based on lifetime
perspective and according to the most severe episode ever
experienced. The AT, AT/AU, and AU patients included in our
study were classified as having severe AA, whereas the patchy AA
patients were classified as having mild AA. Two hundred patients
presented with patchy AA, 34 with AT, 26 with AT/AU, and 187 with
AU. 126/449 patients reported a family history of AA (28.1%),
defined as having at least one first- or second-degree relative with
AA (Blaumeiser et al., 2006).
A personal history of atopic disease was determined by asking
patients whether they had ever suffered from atopic dermatitis,
allergic rhinitis, and asthma.
The control group was comprised of 473 healthy unrelated sex
and age-matched anonymous blood donors. Patients and controls
were all of Central European origin.
Ethical approval for the study was obtained from the
Ethics Committees of the University Hospitals Bonn, Du¨sseldorf,
and Antwerp. Written informed consent was obtained before
taking blood from AA patients and controls. The study was
conducted in concordance with the Declaration of Helsinki
Principles.
Laboratory methods
DNA was extracted from peripheral blood leukocytes according to
standard methods. PCR fragments were amplified as described
previously (Smith et al., 2006). The mutation R501X creates a new
restriction site NlaIII (¼Hin1II, Fermentas) that was used before
resolving the digest on 13% polyacrylamide gels (49:1). The digest of
the 2282del4 mutation was performed with DraIII (¼AdeI,
Fermentas) and resolved on 3% agarose gels. The genotype of the
two individuals homozygous for R501X was confirmed by sequen-
cing using independent pairs of PCR primers.
Statistical analysis
Genotype frequencies of the cases and controls were tested for
deviation from Hardy–Weinberg equilibrium using the w2-test (1 df).
Genotypic distributions between cases and control subjects were
compared using the Cochran–Armitage trend test (Cochran, 1954;
Armitage, 1955). The trend test is a method of directing w2-test
toward narrow alternatives. The test is sensitive to the linearity
between response variable and experimental variables and detects
trends that would remain undetected by cruder methods (Sasieni,
1997). In addition, the trend test is still valid when genotype
frequencies do not comply with Hardy–Weinberg proportions. Allele
frequencies were compared with the Fisher’s exact test (Fisher,
1922). All these tests are included in the statistical package SAS
version 9.1 (SAS Institute, Cary, NC).
Some of our subgroup analyses were independent from testing of
the primary hypotheses. We did not correct for multiple testing, as
we considered these to be exploratory analyses. Independent
replication of these results is therefore needed.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank all patients and controls for their participation in the study. We
thank Dr Katia Seymons for her assistance with patient recruitment. One
hundred and forty-seven of the DNA samples from the anonymous blood
donors were kindly provided by Professor Bernd Po¨tzsch (Institute of
Experimental Hematology and Transfusion Medicine, University of Bonn,
Germany) and Dr Elisabeth Mangold (Institute of Human Genetics, University
of Bonn, Germany). Regina C Betz is a recipient of an Emmy Noether grant
from the German research foundation (DFG) and of a grant from the BONFOR
programme of the Medical Faculty of the University of Bonn, Germany.
Markus M No¨then is recipient of a grant of the Alfried Krupp von Bohlen und
Halbach-Stiftung.
REFERENCES
Armitage P (1955) Test for linear trend in proportions and frequencies.
Biometrics 11:375–86
Barahamani N, De Andrade M, Slusser J, Zhang Q, Duvic M (2002)
Interleukin-1 receptor antagonist allele 2 and familial alopecia areata.
J Invest Dermatol 118:335–7
Barker JN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP et al. (2007) Null
mutations in the filaggrin gene (FLG) determine major susceptibility to
early-onset atopic dermatitis that persists into adulthood. J Invest
Dermatol 127:564–7
Blaumeiser B, van der Goot I, Fimmers R, Hanneken S, Ritzmann S, Seymons
K et al. (2006) Familial aggregation of alopecia areata. J Am Acad
Dermatol 54:627–32
Cochran W (1954) Some methods for strengthening the common w2 test.
Biometrics 10:417–51
Colombe BW, Lou CD, Price VH (1999) The genetic basis of alopecia areata:
HLA associations with patchy alopecia areata versus alopecia totalis and
alopecia universalis. J Investig Dermatol Symp Proc 4:216–9
de Andrade M, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M
(1999) Alopecia areata in families: association with the HLA locus.
J Investig Dermatol Symp Proc 4:220–3
Duvic M, Welsh EA, Jackow C, Papadopoulos E, Reveille JD, Amos C (1995)
Analysis of HLA-D locus alleles in alopecia areata patients and families.
J Invest Dermatol 104:5S–6S
Entz P, Blaumeiser B, Betz RC, Lambert J, Seymons K, Eigelshoven S et al.
(2006) Investigation of the HLA-DRB1 locus in alopecia areata. Eur J
Dermatol 16:363–7
Fisher RA (1922) On the interpretation of w2 for contingency tables, and the
calculation of P. J R Statist Soc 85:87–94
Galbraith GM, Pandey JP (1995) Tumor necrosis factor alpha (TNF-alpha)
gene polymorphism in alopecia areata. Hum Genet 96:433–6
Goh C, Finkel M, Christos P, Sinha A (2006) Profile of 513 patients with
alopecia areata: associations of disease subtypes with atopy, auto-
immune disease and positive family history. J Eur Acad Dermatol
Venereol 20:1055–60
Ikeda T (1965) A new classification of alopecia areata. Dermatologica
131:421–45
Irvine AD, McLean WH (2006) Breaking the (un)sound barrier: filaggrin is a
major gene for atopic dermatitis. J Invest Dermatol 126:1200–2
Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M (1998)
Alopecia areata and cytomegalovirus infection in twins: genes versus
environment? J Am Acad Dermatol 38:418–25
Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher
T et al. (2006) Filaggrin loss-of-function mutations predispose to
2542 Journal of Investigative Dermatology (2007), Volume 127
RC Betz et al.
The Filaggrin Gene in Alopecia Areata
phenotypes involved in the atopic march. J Allergy Clin Immunol
118:866–71
Morar N, Cookson WO, Harper JI, Moffatt MF (2007) Filaggrin mutations in
children with severe atopic dermatitis. J Invest Dermatol doi:10.1038/
sj.jid.5700739
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D et al.
(2004) Alopecia areata investigational assessment guidelines – Part II.
National Alopecia Areata Foundation. J Am Acad Dermatol 51:440–7
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al.
(2006) Common loss-of-function variants of the epidermal barrier protein
filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet
38:441–6
Ruether A, Stoll M, Schwarz T, Schreiber S, Folster-Holst R (2006) Filaggrin
loss-of-function variant contributes to atopic dermatitis risk in the
population of Northern Germany. Br J Dermatol 155:1093–4
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III (1995) Incidence
of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.
Mayo Clin Proc 70:628–33
Sasieni PD (1997) From genotypes to genes: doubling the sample size.
Biometrics 53:1253–61
Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao
Y et al. (2006) Loss-of-function mutations in the gene encoding filaggrin
cause ichthyosis vulgaris. Nat Genet 38:337–42
Stemmler S, Parwez Q, Petrasch-Parwez E, Epplen JT, Hoffjan S (2007) Two
common loss-of-function mutations within the filaggrin gene predispose
for early onset of atopic dermatitis. J Invest Dermatol 127:722–4
Tan E, Tay YK, Goh CL, Chin Giam Y (2002) The pattern and profile of
alopecia areata in Singapore – a study of 219 Asians. Int J Dermatol
41:748–53
Tazi-Ahnini R, Cork MJ, Gawkrodger DJ, Birch MP, Wengraf D,
McDonagh AJ et al. (2002a) Role of the autoimmune regulator (AIRE)
gene in alopecia areata: strong association of a potentially functional
AIRE polymorphism with alopecia universalis. Tissue Antigens
60:489–95
Tazi-Ahnini R, Cox A, McDonagh AJ, Nicklin MJ, di Giovine FS, Timms JM
et al. (2002b) Genetic analysis of the interleukin-1 receptor antagonist
and its homologue IL-1L1 in alopecia areata: strong severity association
and possible gene interaction. Eur J Immunogenet 29:25–30
Tazi-Ahnini R, di Giovine FS, McDonagh AJ, Messenger AG, Amadou C,
Cox A et al. (2000) Structure and polymorphism of the human gene
for the interferon-induced p78 protein (MX1): evidence of association
with alopecia areata in the Down syndrome region. Hum Genet
106:639–45
Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A et al.
(2006) Loss-of-function variations within the filaggrin gene predispose
for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol
118:214–9
Weidinger S, Rodriguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T et al. (2007)
Filaggrin mutations strongly predispose to early-onset and extrinsic
atopic dermatitis. J Invest Dermatol 127:724–6
Young E, Bruns HM, Berrens L (1978) Alopecia areata and atopy
(proceedings). Dermatologica 156:306–8
www.jidonline.org 2543
RC Betz et al.
The Filaggrin Gene in Alopecia Areata
